Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180

Therapeutic Drug Monitoring

Volumn 18, Issue 1, 1996, Pages 65-72

  Miller, James J ^a   Straub Jr , Rudolph W ^a   Valdes Jr , Roland ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Digibind therapy; Digoxin; Digoxin like immunoreactive factor; Intermethod comparison; Specificity

Indexed keywords

BILIRUBIN; DIGITALIS LIKE FACTOR; DIGITOXIN; DIGOXIN; DIHYDRODIGOXIN; HEMOGLOBIN; INTRALIPID; MONOCLONAL ANTIBODY; TRIACYLGLYCEROL;

ARTICLE; CONTROLLED STUDY; CROSS REACTION; DIGOXIN BLOOD LEVEL; DRUG MONITORING; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; RELIABILITY;

ANTIBODIES, MONOCLONAL; BIOTRANSFORMATION; CARDENOLIDES; CARDIOTONIC AGENTS; CHEMILUMINESCENT MEASUREMENTS; CROSS REACTIONS; DIGOXIN; EVALUATION STUDIES; HUMANS; SAPONINS;

EID: 0030023124     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199602000-00011     Document Type: Article

References (22)

1. Ried LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Ther Drug Monit 1990;12:72-8.
2. Howanitz PJ, Steindel SJ. Digoxin therapeutic drug monitoring practices: a College of American Pathologists Q-probes study of 666 institutions and 18676 toxic levels. Arch Pathol Lab Med 1993;117:684-90.
3. Piergies AA, Worwag EM, Atkinson AJ Jr. A concurrent audit of high digoxin plasma levels. Clin Pharmacol Ther 1994;55:353-8.
4. Lewis RP. Digitalis. In: Leier CV, ed. Cardiotonic drugs: a clinical review. 2nd ed. New York: Marcel Dekker, 1991: 107-77. (Fundamental and clinical cardiology; vol 2).
5. Soldin SJ. Digoxin - issues and controversies. Clin Chem 1986;32:5-12.
6. Bednarczyk B, Soldin SJ, Gasinska I, D'Costa M, Perrot L. Improved receptor assay for measuring digoxin activity. Clin Chem 1988;34:393-7.
7. Valdes R Jr, Brown B, Graves S. Variable cross-reactivity of digoxin metabolites in digoxin immunoassays. Am J Clin Pathol 1984;82:210-3.
8. Miller JJ, Straub R, Valdes R Jr. Digoxin immunoassay with cross-reactivity of digoxin metabolites proportional to their biological activity. Clin Chem 1994;40:1898-903.
9. Valdes R Jr. Endogenous digoxin-like immunoreactive factors: impact on digoxin measurements and potential physiological implications. Clin Chem 1985;31:1525-32.
10. Cornbleet PJ, Gochman N. Incorrect least-squares regression coefficients in method-comparison analysis. Clin Chem 1979;25:432-8.
11. Konings H. Use of Deming regression in method-comparison studies. Surv Immunol Res 1982;1:371-4.
12. Lau BWC, Valdes R Jr. Criteria for identifying endogenous compounds as digoxin-like immunoreactive factors in humans. Clin Chim Acta 1988;175:67-78.
13. Loucari-Yiannakou E, Yiannakou L, Souvatzoglou A, Diamandis EP. Radioimmunoassay of digoxin in serum using monoclonal antibodies and assessment of interference by digoxin-like immunoreactive substances. Ther Drug Monit 1990;12:195-200.
14. Tietz NW, ed. Textbook of clinical chemistry. Philadelphia: Saunders, 1986.
15. Datta P, Larsen F, Xu L, Kenny M, Hinz V, Klee G. A multicenter evaluation of the ACS digoxin assay [Abstract]. Clin Chem 1994;40:1071.
16. Naomi S, Graves S, Lazarus M, Williams GH, Hollenberg NK. Variation in apparent serum digitalis-like factor levels with different digoxin antibodies: the "immunochemical fingerprint." Am J Hypertens 1991;4:795-801.
17. Ujhelyi MR, Cummings DM, Green PJ, Ellison MJ, Vlasses PH. Effect of digoxin fab antibodies on five digoxin immunoassays. Ther Drug Monit 1990;12:288-92.
18. Ujhelyi MR, Green PJ, Cummings DM, Robert S, Vlasses PH, Zarowitz BJ. Determination of free serum digoxin concentrations in digoxin toxic patients after administration of digoxin fab antibodies. Ther Drug Monit 1992;14:147-54.
19. Kampa IS. Prolonged effect of Fab fragments on various digoxin immunoassays [Abstract]. Clin Chem 1991;37:1001.
20. Skogen WF, Rea MR, Valdes R Jr. Improved interassay correlation of digoxin results in patients with and without renal failure by elimination of digoxin-like immunoreactive factors. Clin Chem 1987;33:837-9.
21. Matheke ML, Valdes R Jr. Antibody specificity reduces interference by endogenous digoxin-like immunoreactive factors. J Clin Immunoassay 1989;12:115-21.
22. Miller JJ, Hess PP, Valdes R Jr. The effect of digoxin on digoxin-like immunoreactive factor (DLIF) interference varies among digoxin assays [Abstract]. J Clin Immunoassay 1992;15:63.